New Analysis from Investigational IMPROVE-IT Study Shows VYTORINÂ® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Sy